Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia

• Status: Completed
• Trial end date: 2009-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the effectiveness of two antipsychotic medications, Risperdal® Consta® versus Abilify®, over a 2-year treatment period in the long-term maintenance of patients with schizophrenia.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
• Collaborator: Janssen, LP
• Treatments: Aripiprazole; Risperidone

Criteria

Inclusion Criteria:

• Patients with diagnosis of schizophrenia

• Patient has had at least 2 psychotic relapses in the two years prior to study entry

• patient is not adequately benefiting from their current antipsychotic medication

Exclusion Criteria:

• Patients that have been hospitalized or had major medication changes within 2 months of study entry

• Patients currently experiencing, or who have experienced worsening of disease symptoms within 2 months of study entry

• Patients currently using clozapine or carbamazepine

• Patients who have undergone electroconvulsive therapy or depot antipsychotic treatment within 6 months prior to study entry

• pregnant or breast-feeding